Literature DB >> 25444138

Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization.

Beom Kyung Kim1,2, Kyung Ah Kim3, Chansik An4, Eun Jin Yoo1, Jun Yong Park1,2, Do Young Kim1,2, Sang Hoon Ahn1,2, Kwang-Hyub Han1,2,5, Seung Up Kim1,2, Myeong-Jin Kim4.   

Abstract

BACKGROUND & AIMS: Computed tomography (CT) and magnetic resonance imaging (MRI) play important roles in diagnosis and staging of hepatocellular carcinoma (HCC). However, prognostic roles of radiological characteristics are not yet determined.
METHODS: Eighty-eight patients treated with chemoembolization were analysed. Radiological parameters at baseline were assessed in all patients using both dynamic CT and MRI. Treatment responses were assessed using modified RECIST 4 weeks after the first chemoembolization.
RESULTS: Gross vascular invasion (GVI), bile duct invasion, irregular tumour margin (ITM), peripheral ragged enhancement (PRE) and satellite nodules on CT or MRI were associated with non-response (stable disease or progression) after chemoembolization respectively (all P ≤ 0.05). GVI, ITM and PRE on CT or MRI were also independently associated with poor overall survival (OS) respectively (all P ≤ 0.05). Using these results, a prognostic scoring system for CT and MRI were developed; 0, absence of all three features (GVI, ITM and PRE); 1, presence of one feature; 2, presence of two features; and 3, presence of three features. After adjusting tumour size, tumour number and alpha-foetoprotein level, both CT and MRI scores were independently associated with OS (both P < 0.001). Patients with CT or MRI score ≥2 had a worse OS than those with score <2 (adjusted hazard ratios, 3.837 and 2.938 respectively). MRI-specific parameters such as signal intensity on T2- or T1-weighted images, fat signal or hyperintensity on diffusion-weighted images did not have prognostic value (all P > 0.05).
CONCLUSIONS: Radiological parameters by CT and MRI may be useful in biological characterization of tumours and prognostification for HCC treated with chemoembolization.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  chemoembolization; computed tomography; hepatocellular carcinoma; magnetic resonance imaging; prognosis

Mesh:

Substances:

Year:  2015        PMID: 25444138     DOI: 10.1111/liv.12751

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  10 in total

Review 1.  Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

Authors:  Yì-Xiáng J Wáng; Thierry De Baere; Jean-Marc Idée; Sébastien Ballet
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

2.  Serum alanine aminotransferase to hemoglobin ratio and radiological features predict the prognosis of postoperative adjuvant TACE in patients with hepatocellular carcinoma.

Authors:  Zicong Xia; Yulou Zhao; Hui Zhao; Jing Zhang; Cheng Liu; Wenwu Lu; Lele Wang; Kang Chen; Junkai Yang; Jiahong Zhu; Wenjing Zhao; Aiguo Shen
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

3.  Hepatocellular Carcinoma with Irregular Rim-Like Arterial Phase Hyperenhancement: More Aggressive Pathologic Features.

Authors:  Hyungjin Rhee; Chansik An; Hye-Young Kim; Jeong Eun Yoo; Young Nyun Park; Myeong-Jin Kim
Journal:  Liver Cancer       Date:  2018-05-15       Impact factor: 11.740

4.  MRI Findings and Prediction of Time to Progression of Patients with Hepatocellular Carcinoma Treated with Drug-eluting Bead Transcatheter Arterial Chemoembolization.

Authors:  Seungsoo Lee; Kyung Ah Kim; Mi-Suk Park; Sun Young Choi
Journal:  J Korean Med Sci       Date:  2015-06-10       Impact factor: 2.153

5.  Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma.

Authors:  David J Pinato; Madhava Pai; Isabella Reccia; Markand Patel; Alexandros Giakoustidis; Georgios Karamanakos; Azelea Rushd; Shiraz Jamshaid; Alberto Oldani; Glenda Grossi; Mario Pirisi; Paul Tait; Rohini Sharma
Journal:  BMC Cancer       Date:  2018-02-20       Impact factor: 4.430

6.  Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma.

Authors:  Osman Öcal; Michael Ingrisch; Muzaffer Reha Ümütlü; Bora Peynircioglu; Christian Loewe; Otto van Delden; Vincent Vandecaveye; Bernhard Gebauer; Christoph J Zech; Christian Sengel; Irene Bargellini; Roberto Iezzi; Alberto Benito; Maciej Pech; Peter Malfertheiner; Jens Ricke; Max Seidensticker
Journal:  Br J Cancer       Date:  2021-10-22       Impact factor: 7.640

7.  The Prognostic Value of Baseline Clinical and Radiologic Imaging Features in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab.

Authors:  Muhammad O Awiwi; Khaled M Elsayes; Yehia I Mohamed; Lina Altameemi; Migena Gjoni; Omayr Muhammad Irshad; Ahmed Sayed Ahmed; Ahmad O Kaseb; Usama Salem
Journal:  J Hepatocell Carcinoma       Date:  2022-08-30

Review 8.  Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy.

Authors:  Lucia Cerrito; Maria Elena Ainora; Carolina Mosoni; Raffaele Borriello; Antonio Gasbarrini; Maria Assunta Zocco
Journal:  Cancers (Basel)       Date:  2022-09-24       Impact factor: 6.575

Review 9.  Imagiological Diagnosis of Gastrointestinal Diseases - Diagnostic Criteria of Hepatocellular Carcinoma.

Authors:  Pedro Boal Carvalho; Eduardo Pereira
Journal:  GE Port J Gastroenterol       Date:  2015-05-11

10.  Prediction of prognostic risk factors in hepatocellular carcinoma with transarterial chemoembolization using multi-modal multi-task deep learning.

Authors:  Qiu-Ping Liu; Xun Xu; Fei-Peng Zhu; Yu-Dong Zhang; Xi-Sheng Liu
Journal:  EClinicalMedicine       Date:  2020-06-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.